Search - tctmd.com

Displaying 41 - 60 of 211

Sort: Relevancy | Date

News Conference News ESC 2024

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Michael O'Riordan

September 01, 2024

News Daily News

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

Michael O'Riordan

August 19, 2024

News Daily News

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

L.A. McKeown

August 05, 2024

News Daily News

Semaglutide May Ease Tobacco Use, Study Suggests

Todd Neale

August 01, 2024

News Daily News

Amputation Risks Higher After Revascularization in Younger vs Older PAD Patients

L.A. McKeown

July 24, 2024

News Daily News

No Uptick in Suicidal Thinking With GLP-1 Drugs: Medicare Data

Yael L. Maxwell

July 15, 2024

News Daily News

Semaglutide Has Similar Benefits in Women and Men With HFpEF

Todd Neale

June 26, 2024

News Daily News

AHA Celebrates a Century by Looking Back, and Forward

Shelley Wood

June 10, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ACC 2024

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

L.A. McKeown

April 06, 2024

News Conference News

Lifestyle Changes Can Curb CVD Risk After Adverse Pregnancy Outcomes

Yael L. Maxwell

March 26, 2024

News Opinion CV Team Dispatch

February 2024 Dispatch for the CV Team

L.A. McKeown

February 01, 2024

News Daily News

Universal Risk Tool Works Well in Both Primary and Secondary Prevention

Michael O'Riordan

February 01, 2024

News Opinion CV Team Dispatch

January 2024 Dispatch for the CV Team

L.A. McKeown

January 01, 2024

News Daily News

‘Smoldering Epidemic’ of CVD Risk Factors in Middle-Aged Adults

Michael O'Riordan

November 21, 2023

News Daily News

Mortality Risk Varies Among Patients With Very High LDL Levels

Michael O'Riordan

November 17, 2023

News Conference News AHA 2023

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

Todd Neale

November 13, 2023

News Daily News

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

Yael L. Maxwell

October 19, 2023

News Daily News

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

L.A. McKeown

October 10, 2023

News Opinion CV Team Dispatch

October 2023 News Roundup

L.A. McKeown

October 01, 2023

Advertisement

FINEARTS-HF: Benefit of Finerenone Extends to HFmrEF and HFpEF Patients

Both SGLT2 and GLP-1 Drugs Help Heart and Kidneys in Type 2 Diabetes

FINEARTS-HF: Topline Results Support Role for Finerenone in Mildly Reduced or Preserved EF

Semaglutide May Ease Tobacco Use, Study Suggests

Amputation Risks Higher After Revascularization in Younger vs Older PAD Patients

No Uptick in Suicidal Thinking With GLP-1 Drugs: Medicare Data

Semaglutide Has Similar Benefits in Women and Men With HFpEF

AHA Celebrates a Century by Looking Back, and Forward

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

STEP-HFpEF DM Trial Hints at Semaglutide HF Effects Beyond Pounds Shed

Lifestyle Changes Can Curb CVD Risk After Adverse Pregnancy Outcomes

February 2024 Dispatch for the CV Team

Universal Risk Tool Works Well in Both Primary and Secondary Prevention

January 2024 Dispatch for the CV Team

‘Smoldering Epidemic’ of CVD Risk Factors in Middle-Aged Adults

Mortality Risk Varies Among Patients With Very High LDL Levels

ESPRIT: Intensive BP-Lowering Reduces MACE in Chinese Patients

Rosuvastatin, Atorvastatin: Similar Efficacy in LODESTAR, Some Differing Signals

Diabetes in Middle Age Linked to Earlier CVD Risk: Danish Study

October 2023 News Roundup

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content